Displaying 31 (all) recruiting clinical trials.
-
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
The purpose of this two part study is to evaluate the safety (Stage 1 and Stage 2) and efficacy (Stage 2) of NRTX-1001 in subjects ...Phase
Interventional
-
A Phase I/IIa Dose Escalation Study Evaluating the Safety Tolerability and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults with Radiation-Induced Xerostomia and Hyposalivation
This is a Phase 1/2a study testing whether administering the new study medicine RXRG001 (a lipid nanoparticle containing circular mRNA) directly into the ducts ...
Phase
Interventional
-
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Despite clear advances that have been taking place in the treatment of advanced RCC in recent years, there are still unmet medical needs and opportunities ...Phase
Interventional
-
A Modular Phase I/II Open-label Multicentre Study to Evaluate the Safety PK PD Immunogenicity and Efficacy of AZD4512 Monotherapy or in Combination with other Anticancer agent(s) in subjects with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I/II study testing whether the new medicine AZD4512 is safe, effective, and well-tolerated in patients with B-cell Non-Hodgkin Lymphoma (B-NHL ...
Phase
Interventional
-
A Phase 1b/2 Study of AZD0120 (also known as GC012F) a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light ...Phase
Interventional
-
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic NSCLC KaRAnaSa (ISA-4)
This is a study in which patients have a specific change in their cancer cells called a KRAS G12C mutation, which means one tiny part ...
Phase
Interventional
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
This is a Phase 1/2 study testing a new drug called mRNA-4359 in people who have solid tumors: a type of cancer that can ...
Phase
Interventional
-
A Phase 1/2a Open-label Study of VS-7375 a KRAS G12D (ON/OFF) Inhibitor as Monotherapy and in Combination in Patients with Advanced KRAS G12D-Mutant Solid Tumors
VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D inhibitor. VS-7375 demonstrated potent inhibition of KRAS G12D-mutated-dependent signal transduction and cancer cell viability ...Phase
Interventional
-
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
This is a study testing a new medicine called Selinexor (small-molecule drug) in children and young adults who were recently diagnosed with a brain tumor ...
Phase
Interventional
-
A Phase 1/2 Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
This is a Phase 1/2 study testing a new oral cancer drug called S241656 (BDTX-4933 - an investigational anti-cancer drug) in patients whose cancers have ...
Phase
Interventional
